CNX-2006 25mg
CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
| Trivial name | CNX-2006 25mg |
| Catalog Number | A13755-25 |
| Alternative Name(s) | N-(3-((2-((4-((1-(2-fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide |
| Molecular Formula | C26H27F4N7O2 |
| CAS# | 1375465-09-0 |
| SMILES | COC1=C(C=CC(=C1)NC2CN(C2)CCF)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F |
| Size | 25mg |
| Supplier Page | http://www.adooq.com/cnx-2006.html |